Decreased SATB1 expression promotes AML cell proliferation through NF-κB activation

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Special AT-rich sequence-binding protein 1 (SATB1) is a chromatin-remodeling protein involved in gene regulation across various cancers.
• SATB1's role appears context-dependent, with up-regulation linked to solid tumor progression but down-regulation observed in T cell leukemia/lymphoma.

Purpose of the Study:

• To investigate the expression and function of SATB1 in acute myeloid leukemia (AML).
• To elucidate the mechanisms by which SATB1 influences AML cell behavior and tumorigenesis.

Main Methods:

• qRT-PCR and Western blot were used to assess SATB1 mRNA and protein levels in AML patient samples.
• SATB1 was knocked down in HL-60 leukemia cells using shRNAs to analyze proliferation, cell cycle, and invasiveness in vitro.
• A murine model was utilized to evaluate the in vivo role of SATB1 in tumorigenicity, alongside global gene expression analysis.

Main Results:

• SATB1 expression was significantly reduced in AML patients compared to healthy controls and increased upon remission.
• SATB1 knockdown in HL-60 cells led to increased proliferation, accelerated S phase entry, and enhanced tumor growth in vivo.
• Gene expression analysis revealed SATB1 knockdown impacts NF-κB, MAPK, and PI3K/Akt signaling pathways, with increased nuclear NF-κB p65.

Conclusions:

• Reduced SATB1 expression promotes AML cell proliferation, potentially via activation of the NF-κB signaling pathway.
• SATB1 may serve as a predictive biomarker for treatment response in acute myeloid leukemia.